⌘K
Loading ticker…
As of 2026-08-21, Theriva Biologics, Inc. (TOVX) has a 3-month relative strength percentile of 18 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 44. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.3%, relative volume 0.95×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
TOVX appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $38K notional.
Held by 1 ETFs · $38K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $38K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TOVX Jan avg: 18.62% median: 0.90% win: 50% σ: 57.32% n: 4 2022-10-14 → 2026-07-31 | TOVX Feb avg: 4.10% median: 5.01% win: 50% σ: 9.76% n: 4 2022-10-14 → 2026-07-31 | TOVX Mar avg: -11.81% median: -12.25% win: 25% σ: 12.99% n: 4 2022-10-14 → 2026-07-31 | TOVX Apr avg: 20.47% median: 6.47% win: 50% σ: 44.91% n: 4 2022-10-14 → 2026-07-31 | TOVX May avg: -28.65% median: -29.36% win: 25% σ: 31.38% n: 4 2022-10-14 → 2026-07-31 | TOVX Jun avg: 5.12% median: -6.30% win: 25% σ: 26.67% n: 4 2022-10-14 → 2026-07-31 | TOVX Jul avg: -11.85% median: -8.63% win: 25% σ: 16.28% n: 4 2022-10-14 → 2026-07-31 | TOVX Aug avg: -9.56% median: -8.11% win: 33% σ: 11.43% n: 3 2022-10-14 → 2026-07-31 (current) | TOVX Sep avg: -25.03% median: -1.20% win: 33% σ: 44.71% n: 3 2022-10-14 → 2026-07-31 | TOVX Oct avg: -15.12% median: -19.91% win: 25% σ: 14.48% n: 4 2022-10-14 → 2026-07-31 | TOVX Nov avg: 3.51% median: -3.03% win: 25% σ: 20.78% n: 4 2022-10-14 → 2026-07-31 | TOVX Dec avg: -16.44% median: -25.12% win: 25% σ: 26.05% n: 4 2022-10-14 → 2026-07-31 |